Goodrich Lab

The Goodrich Lab research program is focused on using new methods to stimulate immune response in patients with cancer and to prevent infectious diseases. A clinical application of new technology developed in his lab is for treatment of patients with advanced stage ovarian cancer. In addition, his group is focused on developing methods to generate new vaccine candidates for infectious diseases in humans and animals. The current program of work includes research on new vaccine formulations for SARS-CoV-2, Tuberculosis, Human and Avian Influenza and African Swine Fever, using a technology platform for production of vaccines invented in collaboration with colleagues at Colorado State University.

research project

Production and Testing of SARS-CoV-2 Vaccine

Manufacturing of a vaccine for COVID-19 using the SolaVAX technology platform. This work includes developing GMP manufacturing and characterization of immune response in animal models.

research project

Development of a vaccine for human influenza

Testing of adjuvant formulations in mouse and ferret animal models. Characterization of immunological response and protection from live challenge.

research project

Development of a vaccine for Avian influenza

Testing of adjuvant formulations and delivery routes in poultry. This work focuses on oral and mucosal routes of delivery.

research project

Development of a vaccine for African Swine Fever

Includes an attenuated virus and adjuvant formulations intended to promote cellular immune responses. This work includes evaluation of immunological response and protection against challenge with live virus.

research project

Development of Photochemical Devices for pathogen inactivation of blood products and large scale manufacturing of vaccine formulations

Prototyping and development of devices and disposables that allow for large scale treatment of blood and biological solutions. Applications include treatment of blood products for transfusion and vaccine batches for large volume production.

Publications

Emerging Pathogen Threats in Transfusion Medicine: Improving Safety and Confidence with Pathogen Reduction Technologies
Cardoso M, Ragan I, Hartson L, Goodrich RP. Pathogens. 2023 Jul 5;12(7):911. doi: 10.3390/pathogens12070911. PMID: 37513758

SARS-CoV-2 seroprevalence among blood donors in Uganda: 2019-2022.
Bloch EM, Kyeyune D, White JL, Ddungu H, Ashokkumar S, Habtehyimer F, Baker O, Kasirye R, Patel EU, Grabowski MK, Musisi E, Moses K, Hume HA, Lubega I, Shrestha R, Motevalli M, Fernandez RE, Reynolds SJ, Redd AD, Wambongo Musana H, Dhabangi A, Ouma J, Eroju P, de Lange T, Fowler MG, Musoke P, Stramer SL, Whitby D, Zimmerman PA, McCullough J, Sachithanandham J, Pekosz A, Goodrich R, Quinn TC, Ness PM, Laeyendecker O, Tobian AAR. Transfusion. 2023 Jul;63(7):1354-1365. doi: 10.1111/trf.17449. Epub 2023 Jun 16. PMID: 37255467

Pathogen reduction of monkeypox virus in plasma and whole blood using riboflavin and UV light.
Izabela K Ragan, Lindsay M Hartson, Elizabeth J Sullivan, Richard A Bowen, Raymond P Goodrich (2023) PLoS One 18 (1), e0278862

The Mirasol Evaluation of Reduction in Infections Trial (MERIT) : study protocol for a randomized controlled clinical trial.
Aaron Tobian; Ronnnie Kasirye; Heather Hume; Evan Bloch; Irene Lubega; Dorothy Kyeyune; Ruchee Shrestha; Henry Ddungu; Hellen Wambongo Musana; Aggrey Dhabangi; Joseph Ouma; Priscilla Eroju; Telsa de Lange; Michael Tartakovsky; Jodie White; Ceasar Kakura; Mary Glenn Fowler; Philippa Musoke; Monica Nolan; Kate Grabowski; Lawrence Moulton; Susan Stramer; Denise Whitby; Peter Zimmerman; Deo Wabwire; Isaac Kajja; Jeffrey McCullough; Raymond Goodrich; Thomas Quinn; Robert Cortes; Paul Ness (2022) 23(1):  1-13.

Formulating Autologous Therapies for Cancer Autologous: tumor cells engineered for immune system stimulation can target unique metabolic, genomic, and phenotypic characteristics of cancer cells.
RP Goodrich, A Guth, J Weston, T Opgenorth, G Gordon (2021) BioPharm International 34 (12), 18-20.

more publications

People

Ray Goodrich
Ray Goodrich, Ph.D.

Lab Principal Investigator [PI]
Professor

Noelia Altina
Noelia Altina, Ph.D., M.S.

Research Scientist I

Placeholder Image
Terry Khat

Research Scientist

Placeholder Image
Kim Arnett

Coordinator

Arielle Glass
Arielle Glass, M.S.

Graduate Research Assistant

news and updates view all

March 22, 2021 Coronavirus vaccines are rolling out across the world. So why are CSU scientists still working to develop new ones?

Researchers at Colorado State University with Ray Goodrich are working on four COVID-19 vaccine candidates, one of which is nearing human clinical trials.
February 5, 2021 Researchers turn to proven process for ASF vaccine development

Ray Goodrich partners with Okoth to create an inactivated ASF vaccine that maintains the structure of the virus as close to the natural pathogen as possible.
September 21, 2020 CSU secures $3.1 million from NIH to advance SolaVAX coronavirus vaccine research

A research team led by Ray Goodrich was awarded a $3.1 million base contract to continue development of a coronavirus vaccine candidate known as SolaVAX™.